Illumina selected to help bring precision medicine into everyday healthcare in Singapore
PR Newswire•02/11/2026•20:00 ET
2
Key Highlights
- ➤SG-INSIGHT to sequence approximately 450,000 Singapore residents’ whole genomes
- ➤Illumina selected through an international competitive tender for Phase III
- ➤Phase III extends precision-medicine research to patients across Singapore’s public healthcare system
- ➤Singapore facility will handle sample preparation, sequencing, and genomic data analysis
- ➤Phase II covered more than 100,000 genomes from healthy volunteers
Expert Statements
Jacob Thaysen, Chief Executive Officer of Illumina
“Singapore is showing what the future of precision medicine can look like at national scale.”
Jacob Thaysen, Chief Executive Officer of Illumina
“By bringing genomic information closer to everyday healthcare, this programme has the potential to advance understanding of disease, generate evidence that support more informed care decisions, and ultimately move healthcare toward earlier, more precise intervention. We are proud to bring Illumina's technology, expertise and longstanding presence in Singapore to help make that vision possible.”
Patrick Tan, Executive Director of PRECISE
“Phase III builds on nearly a decade of precision medicine in Singapore.”
Patrick Tan, Executive Director of PRECISE
“By extending the programme to patients across the public healthcare system, SG-INSIGHT aims to deepen understanding of how genetic, lifestyle and environmental factors are associated with health and disease. Phase III reflects Singapore's ambition to build a trusted and sustainable precision health ecosystem grounded in the needs and diversity of its population.”
Nilesh Shah, Head of Region, Asia Pacific, Illumina
“For nearly two decades, Singapore has been one of Illumina's most important centres for innovation, manufacturing and talent in Asia Pacific.”
Nilesh Shah, Head of Region, Asia Pacific, Illumina
“Our long-standing relationship with PRECISE represents the next chapter in that commitment - combining Singapore's leadership in precision health with Illumina's local genomic capabilities and regional expertise. We remain committed to investing in the people, technology and partnerships that can help advance genomics responsibly in Singapore and across the region.”
Illumina selected to help bring precision medicine into everyday healthcare in Singapore PR Newswire
SG-INSIGHT study will extend whole-genome sequencing to nearly 1 in 10 Singapore residents, generating evidence to inform how precision medicine could be implemented in Singapore's healthcare system
Get started
Create a free account to read the full story.